Nuvalent, Inc. (NASDAQ:NUVL) Short Interest Update

Nuvalent, Inc. (NASDAQ:NUVL) saw a significant decline in short interest in July. As of July 15th, there was short interest totaling 715,798 shares, a decline of 75.4% from the June 30th total of 2,908,403 shares. Currently, 1.0% of the company’s stock are sold short. Based on an average daily trading volume, of 1,606,073 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NUVL shares. Lifesci Capital downgraded shares of Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 target price for the company. in a report on Tuesday, June 9th. Truist Financial cut shares of Nuvalent from a “buy” rating to a “hold” rating and lowered their target price for the stock from $140.00 to $124.00 in a research note on Tuesday, June 9th. Stifel Nicolaus set a $124.00 price target on Nuvalent in a research report on Tuesday, June 9th. Raymond James Financial downgraded Nuvalent from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvalent in a research report on Tuesday, April 21st. Four equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $127.73.

Insider Buying and Selling at Nuvalent

In other Nuvalent news, CEO James Richard Porter sold 30,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $101.69, for a total transaction of $3,050,700.00. Following the completion of the sale, the chief executive officer owned 324,879 shares in the company, valued at $33,036,945.51. This represents a 8.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alexandra Balcom sold 11,430 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $123.58, for a total value of $1,412,519.40. Following the sale, the chief financial officer directly owned 85,533 shares in the company, valued at $10,570,168.14. This trade represents a 11.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 125,971 shares of company stock worth $13,358,939. 5.02% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Nuvalent

Institutional investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. acquired a new stake in Nuvalent in the 3rd quarter worth about $107,794,000. Wellington Management Group LLP increased its position in shares of Nuvalent by 46.0% during the third quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after acquiring an additional 724,491 shares during the last quarter. Vanguard Group Inc. increased its holdings in Nuvalent by 13.9% in the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock valued at $527,521,000 after purchasing an additional 639,264 shares during the last quarter. Norges Bank purchased a new stake in Nuvalent in the fourth quarter valued at approximately $57,763,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Nuvalent by 32.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock worth $221,826,000 after buying an additional 545,542 shares during the period. Institutional investors and hedge funds own 97.26% of the company’s stock.

Nuvalent Stock Performance

Shares of Nuvalent stock remained flat at $123.96 during trading on Monday. The stock has a market capitalization of $9.79 billion, a price-to-earnings ratio of -20.46 and a beta of 1.14. The company has a 50 day moving average price of $116.34 and a two-hundred day moving average price of $107.58. Nuvalent has a fifty-two week low of $71.13 and a fifty-two week high of $123.99.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same period in the previous year, the business earned ($1.18) earnings per share. Equities research analysts predict that Nuvalent will post -5.74 earnings per share for the current year.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.